Home
overview

This year's Pain Therapeutics event will be a great platform to explore new discoveries in the field. Speakers will share case studies and attendees will have the opportunity to explore new ways to overcome challenges in the development and administration of pain therapeutics. The programme will reflect and hopefully exceed the high standard set by last year's conference.

  • Explore the use of TRP Channels as therapeutic tagets
  • Understand how to apply pre-clinical outcome measures and manage human experimental trials in pain research
  • Hear about the latest advances In translational strategies for chronic neuropathic pain
  • Learn how Pfizer targets Voltage-Gated Sodium Channels for pain therapy

VPs, Managers, Heads, Directors and Associates from the areas of:

  • Pain research
  • Neuroscience drug discovery
  • Pain management
  • Senior Therapeutics and Pain Management Leaders
  • Clinical development-research
  • Business development-licensing
  • Drug delivery
  • Alliance management 
  • Academic institutions
  • Consultancies
  • Pain management devices
  • Investment banks and venture capitalist firms
               

Conference programme

8:30 Registration & Cofee

9:00 Chaiman's Opening Remarks

Praveen Anand

Praveen Anand, Professor of Clinical Neurology, Imperial College London

9:10 LOST IN TRANSLATION: PRECLINICAL OUTCOME MEASURES AND HUMAN EXPERIMENTAL TRIALS IN PAIN RESEARCH

Aldemar Degroot

Aldemar Degroot, Translational Scientist, Astellas Pharma Europe

  • Additional outcome measures in preclinical models
  • Novel models to enhance translational science
  • Human experimental models and translational science
  • Translational science and pain
  • 9:50 TRPV1 AGONIST APPROACHES TO LOCALIZED MANAGEMENT OF CHRONIC PAIN

  •  Bases of nociceptor overactivity
  •  Expression of TRPV1 in hyperactive nociceptors
  • TRPV1 agonist-induced defunctionalization
  • Phase 3 clinical data for neuropathic pain
  • Keith Bley

    Keith Bley, Senior Vice President, Nonclinical R & D, NeurogesX

    Jeffrey Tobias

    Jeffrey Tobias, Chief Medical Officer, NeurogesX

    10:30 Morning Coffee

    11:00 TRPV1 AGONIST AND ANTAGONIST APPROACHES FOR THE TREATMENT OF PAIN

    Daniel Ursu

    Daniel Ursu, Research Scientist - Pain-Migraine DHT, Eli Lilly & Company

  •  Overview on agonist vs. antagonist approaches
  •  Topical vs. systemic application of TRPV1 agonist
  •  TRPV1 agonists: mechanism of action
  •  Pungency prediction of TRPV1 agonists
  • 11:40 TRPA1 AS A TARGET FOR THE TREATMENT OF PAIN

    Stuart Bevan

    Stuart Bevan , Professor of Pharmacology, Kings College London

  • Functions of TRPA1
  • Lessons from TRPA1 knockout mice
  • Effects of pharmacological intervention
  • 12:20 Networking Lunch

    13:40 ADVANCES IN TRANSLATIONAL STRATEGIES FOR CHRONIC NEUROPATHIC PAIN

    Praveen Anand

    Praveen Anand, Professor of Clinical Neurology, Imperial College London

  • Non-invasive objective technique to assess hypersensitive / regenerating nerve fibres
  • Novel skin biopsy selective markers of hypersensitive / regenerating fibres 
  •  Mechanism-based cohorts in genetic, inflammatory, toxic, metabolic neuropathies
  • Human DRG culture models for novel drug development
     
  • 14:20 TRPM8 AGONISTS FOR PAIN TREATMENT

    Rory Mitchell

    Rory Mitchell, Wellcome Trust Fellow , University of Edinburgh

  • The effect of TRPM8 agonists sensory sensitivity in neuropathic and inflammatory chronic pain models
  • Mechanism of action
  • Topical route of application
  • 15:00 Afternoon Tea

    15:20 PITFALLS AND CHALLENGES IN ANIMAL MODELLING OF PAIN

    Odd-Geir Berge

    Odd-Geir Berge, Senior Principal Scientist, AstraZeneca

  •  Confounds of measurement
  •  What’s measured isn’t always what it seems
  •   Bias towards (false) positive outcomes
  •  How do we choose methods and approaches?
  •  Translation across species
  •  Is the rat just a small man, the mouse a small rat?
  • A way forward?
  • 16:00 MINIMISING THE RISKS IN PAIN DRUG DEVELOPMENT

    Paul Passier

    Paul Passier, Associate Scientific Director Exploratory Medicine, Astellas Pharma Europe

  • Strategies in early clinical development (first in man through PoC) to minimize this risk
  • Models involved, examples and flaws of the approach and their contribution to risk reduction
  • How to improve predictability of the dose range and regimen in patients
  • Can we improve responder rate?
  • 16:40 TRANSLATIONAL NEUROPHYSIOLOGICAL BIOMARKERS FOR DRUG DISCOVERY OF ANALGESIC DRUGS

    Martin Koltzenburg

    Martin Koltzenburg, Chair of Clinical Neurophysiology and Deputy Director, Centre for Neuromuscular Disease

  • Ion channel expression in peripheral nociceptors
  • Role of sodium channels for perception of pain
  • Noninvasive analysis of ion channel properties
  • Nerve excitability studies is a new translational biomarker

     

  • 17:20 Chaiman's Closing Remarks and Close of Day One

    8:30 Registration & Cofee

    9:00 Chairman's Opening Remarks

    Jonathan  Stewart

    Jonathan Stewart, Director, Neurology MDC, EU Clinical, GlaxoSmithKline

    9:10 TARGETING VOLTAGE-GATED SODIUM CHANNELS FOR PAIN THERAPY

    Steve England

    Steve England, Associate Research Fellow, Pain Therapeutics, Pfizer

  • Sodium channels in pain signalling
  • Validation of Nav channels as targets for pain therapy
  •  Challenges to the delivery of new Nav channel modulators
  •  Emerging Nav pharmacology
  • 9:50 WHY WERE WE NOT ABLE TO DELIVER BETTER MEDICINES FOR CHRONIC PAIN?

    Joachim Scholpp

    Joachim Scholpp, Director Exploratory Clinical Science, Nycomed

  • Efficacy of currently available medicines
  • Factors determining efficacy
  • Factors determining successful clinical trials
  • Key factors for better medicines
  • 10:30 Morning Coffee

    11:00 PROSTANOID EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE PAIN

    Karen Maubach

    Karen Maubach, Clinical Development Executive, BTG

  • EP4 receptor antagonists
  • Alleviating the symptoms of migraine after an attack
  • BGC20-1531 side-effect profile
  • Neurogenic and inflammatory pain paradigm
     
  • 11:40 INNOVATIONS: PAIN THERAPEUTICS DELIVERY

    Kewal Jain

    Kewal Jain, Chief Executive Officer, Jain PharmaBiotech

  •  Routes and formu;lations
  • Drug delivery
  • Cell and gene therapies
  • 12:20 Networking Lunch

    13:50 MONOAMINE REUPTAKE INHIBITORS - A DISCUSSION OF OCCUPANCY-RESPONSE RELATIONSHIPS FROM PRECLINICAL MODELS TO CLINICAL ANALGESICS

    Jan  Smith

    Jan Smith, Director, Theravance

  • Rationale for monoamine reuptake inhibition
  • Monoamine reuptake inhibitors - preclinical occupancy-response relationships
  • Monoamine reuptake inhibitors - efficacy in chronic pain states
  • 14:30 TARGETING GLIAL CELLS FOR THE TREATMENT OF PAIN

    John Davis

    John Davis , Director, Biology Pain & Neuroexcitability DPU, GlaxoSmithKline

  • Neuronal-glial interactions in pain
  • Role of glia in the central control of pain
  • Therapeutic targets on glia
  • 15:10 CB2 RECEPTOR SELECTIVE AGONISTS IN TREATMENT OF PAIN – FROM SCREENING TO CLINICAL TRIALS

    Neelima Khairatkar-Joshi

    Neelima Khairatkar-Joshi, Vice President and Head, In vitro Biology, Glenmark Research Centre, India

  • Cannabinoids in pain management – Historical perspective
  • CB2 receptor target Biology
  • Screening and CB2 receptor agonist lead identification
  • Efficacy in animal models of pain
  • Clinical trials
  • 15:50 Chairman's Closing Remarks

    16:00 Afternoon Tea and Close of Conference

    +

    Workshops

    INNOVATIONS IN DELIVERY OF THERAPEUTICS FOR PAIN
    Workshop

    INNOVATIONS IN DELIVERY OF THERAPEUTICS FOR PAIN

    Copthorne Tara Hotel
    10th June 2009
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.